Acne (unspecified)

• (2026): Barclay AIS+, Crohns Colitis 360 Feb (e-Collection) 20%
• (2026): Rapparini L+, Am J Clin Dermatol May, Online ahead of print [REVIEW]
• (2025): Honap S+, Clin Gastroenterol Hepatol Jun, Online ahead of print (association)
• (2025): Kim Y+, Clin Exp Allergy Aug, Online ahead of print16% [REVIEW]
• (2025): Lin KJ+, Int J Rheum Dis 28(12), e70492 [REVIEW]

Acne vulgaris ("acne")

• (2026): Ban S+, Int J Dermatol May, Online ahead of print

Cutaneous toxicity / skin toxicity

• (2026): Rapparini L+, Am J Clin Dermatol May, Online ahead of print [REVIEW]

Herpes zoster

• (2023): Mok CC+, Rheumatology (Oxford) May, Online ahead of print
• (2020): Olivera P+, Gastroenterology Jan, Epub ahead of print [REVIEW]

Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))

• (2025): Di Napoli R+, Drug Saf Mar, Online ahead of print14% (pharmacovigilance / pharmacoepidemiology)
• (2025): Di Napoli R+, Drug Saf Jun, Online ahead of print (correction)
• (2025): Nam W+, Int J Clin Pharmacol Ther Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2025): Zhong X+, PLoS One 20(5), e0322849 (pharmacovigilance / pharmacoepidemiology)
• (2024): Goldman A+, Semin Arthritis Rheum May, Online ahead of print (association) (pharmacovigilance / pharmacoepidemiology)
• Negative findings
• (2023): Wei Q+, Front Pharmacol Aug (e-Collection) [REVIEW] (no evidence of increased risk of major adverse cardiovascular events (MACE) )

Thromboembolism

• (2025): Nam W+, Int J Clin Pharmacol Ther Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2020): Rajasimhan S+, Drugs Aging Jun, Online ahead of print [REVIEW]

Headache

• (2022): Chen J+, J Am Acad Dermatol Mar, Online ahead of print [REVIEW]

Creatine phosphokinase (CPK) / creatine kinase increased (hyperCKemia)

• (2025): Kim Y+, Clin Exp Allergy Aug, Online ahead of print13% [REVIEW]

Hyperlipidemia / lipids elevated

• (2025): Kim Y+, Clin Exp Allergy Aug, Online ahead of print12% [REVIEW]
• (2024): Farkas B+, J Clin Med 13(24), 780410%
• (2021): Ng A, Eur J Gastroenterol Hepatol 33(1S Suppl 1), e1090

Gastrointestinal disorder / discomfort

• (2022): Chen J+, J Am Acad Dermatol Mar, Online ahead of print [REVIEW]

Fractures

• (2024): Martinez de la Torre A+, Drug Saf Nov, Online ahead of print (association) (WHO pharmacovigilance database) (pharmacovigilance / pharmacoepidemiology)

Nasopharyngitis

• (2022): Chen J+, J Am Acad Dermatol Mar, Online ahead of print [REVIEW]
• (2017): Shreberk-Hassidim R+, J Am Acad Dermatol 76(4), 745 [REVIEW]

Upper respiratory tract infection

• (2021): Gómez-Arias PJ+, Dermatol Ther (Heidelb) Apr, Online ahead of print [REVIEW]
• (2017): Shreberk-Hassidim R+, J Am Acad Dermatol 76(4), 745 [REVIEW]

Adverse effects / adverse reactions

• (2025): Konzett V+, Ann Rheum Dis Feb, Online ahead of print [REVIEW]
• (2025): Mikaeili B+, Clin Rheumatol Feb, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
• (2025): O'Neill SM+, Semin Arthritis Rheum Nov, Online ahead of print [REVIEW]
• (2024): Strunz PP+, Front Immunol Aug (e-Collection) [REVIEW]
• (2024): Szekanecz Z+, Nat Rev Rheumatol Jan, Online ahead of print [REVIEW]
• (2023): Singh JA, BioDrugs Jun, Online ahead of print [REVIEW]
• (2023): Yang F+, Clin Rheumatol Feb, Online ahead of print [REVIEW]
• (2022): Alves C+, Eur J Clin Pharmacol Oct, Online ahead of print [REVIEW]
• (2022): Daniele S+, J Drugs Dermatol 21(12), 1298-1303 [REVIEW]
• (2022): Elmariah SB+, Am J Clin Dermatol Jun, Online ahead of print [REVIEW]
• (2022): Fleischmann R, Expert Rev Clin Immunol Feb, Online ahead of print [REVIEW]
• (2022): Shalabi MMK+, Skin Therapy Lett 27(1), 4-9 [REVIEW]
• (2021): Wood H+, Int J Dermatol Aug, Online ahead of print [REVIEW]
• Negative findings
• (2026): Lin TL+, Clin Pharmacol Ther Mar, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2025): Shi X+, J Am Acad Dermatol Sep, Online ahead of print